attyloid GmbH is a biomarker company specializing in neurodegenerative diseases. The company provides ultrasensitive assays for quantifying and sizing protein aggregates, such as amyloid-beta and alpha-synuclein oligomers. Its core technology, sFIDA (surface-based fluorescence intensity distribution analysis), enables high specificity and sensitivity in biofluid analysis. attyloid supports pharmaceutical and biotech partners in clinical development, particularly in Alzheimer's and Parkinson's disease, offering both fee-for-service studies and collaborative models.